公开(公告)号：US20240360200A1

公开(公告)日：2024-10-31

申请号：US18663615

申请日：2024-05-14

申请人： DAIICHI SANKYO COMPANY, LIMITED

发明人： Daisuke Nishimiya ,  Hidenori Yano ,  Hidenori Takahashi ,  Shinji Yamaguchi ,  Shiho Ofuchi

IPC分类号： C07K14/81 ,  A61K38/00 ,  A61K38/55 ,  A61K38/57

CPC分类号： C07K14/81 ,  A61K38/55 ,  A61K38/57 ,  C07K14/811 ,  C07K14/8135 ,  A61K38/00 ,  C07K2319/30

摘要： SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.

公开(公告)号：US12083171B2

公开(公告)日：2024-09-10

申请号：US16613521

申请日：2018-05-16

申请人： OCTAPHARMA AG

发明人： Georg Lattner ,  Klaus Tschetschkowitsch ,  Almira Dugic

IPC分类号： A61K38/57 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K47/18

CPC分类号： A61K38/57 ,  A61K9/0029 ,  A61K9/08 ,  A61K9/19 ,  A61K47/183

摘要： The present invention relates to a stable C1-esterase-inhibitor (C1-Inh) preparation, which is liquid or lyophilised, characterised by a histidine content of 5-400 mM but does not contain citrate or phosphate. It further relates to a kit including the C1-Inh preparation.

公开(公告)号：US20240285736A1

公开(公告)日：2024-08-29

申请号：US18655414

申请日：2024-05-06

申请人： Pharming Intellectual Property B.V.

发明人： Sijmen DE VRIES ,  Bruno GIANNETTI

IPC分类号： A61K38/57 ,  A61P9/12

CPC分类号： A61K38/57 ,  A61P9/12

摘要： The present invention relates to the field of medicine, specifically to the prevention and treatment of pre-eclampsia.

公开(公告)号：US12053511B2

公开(公告)日：2024-08-06

申请号：US16903107

申请日：2020-06-16

申请人： BOARD OR REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Tonyia Eaves-Pyles ,  Richard B. Pyles

IPC分类号： A61K38/00 ,  A61K38/57 ,  A61K47/60 ,  A61P1/00 ,  A61P29/00 ,  A61P31/04 ,  A61P37/02 ,  C07K14/81

CPC分类号： A61K38/57 ,  A61K47/60 ,  A61P1/00 ,  A61P29/00 ,  A61P31/04 ,  A61P37/02 ,  C07K14/8139

摘要： The present invention includes a composition and method of modulating a dysregulated gut-derived inflammation following a thermal injury comprising: identifying a mammal in need of treatment for the dysregulated gut-derived inflammation following the thermal injury; and providing the mammal with a recombinant Cystatin 9 (CST9) and Cystatin C (CSTC) in a synergistic amount sufficient to restrain or prevent a life-threatening, unrestrained systemic dysregulated gut-derived inflammation in the mammal caused by the thermal injury.

公开(公告)号：US20240240180A1

公开(公告)日：2024-07-18

申请号：US18426444

申请日：2024-01-30

申请人： University of Massachusetts

发明人： Terence Flotte ,  Christian Mueller ,  Phillip D. Zamore

IPC分类号： C12N15/113 ,  A61K31/713 ,  A61K35/12 ,  A61K38/57 ,  A61K48/00 ,  C07K14/81 ,  C12N7/00 ,  C12N15/67 ,  C12N15/86 ,  C12N15/11

CPC分类号： C12N15/113 ,  A61K31/713 ,  A61K35/12 ,  A61K38/57 ,  A61K48/005 ,  A61K48/0058 ,  C07K14/8125 ,  C12N7/00 ,  C12N15/67 ,  C12N15/86 ,  C12N15/111 ,  C12N2310/141 ,  C12N2310/3519 ,  C12N2320/31 ,  C12N2750/14121 ,  C12N2750/14132 ,  C12N2750/14143

摘要： The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).

公开(公告)号：US20240189361A1

公开(公告)日：2024-06-13

申请号：US18584293

申请日：2024-02-22

申请人： OSIRIS THERAPEUTICS, INC.

发明人： Samson TOM ,  Alla DANILKOVITCH ,  Dana YOO ,  Timothy JANSEN ,  Jin-Qiang KUANG ,  Jennifer Michelle MARCONI

IPC分类号： A61K35/28 ,  A01N1/02 ,  A61K35/50 ,  A61K38/18 ,  A61K38/39 ,  A61K38/57 ,  C12N5/073

CPC分类号： A61K35/28 ,  A01N1/0221 ,  A61K35/50 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/39 ,  A61K38/57 ,  C12N5/0605 ,  C12N2500/02 ,  C12N2501/115 ,  C12N2502/025

摘要： Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

公开(公告)号：US11976108B2

公开(公告)日：2024-05-07

申请号：US17071563

申请日：2020-10-15

申请人： James Cook University

发明人： Alex Loukas ,  Andrew Leech ,  Darren Pickering

IPC分类号： C07K14/81 ,  A61K38/00 ,  A61K38/57 ,  A61K45/06 ,  C07K14/435

CPC分类号： C07K14/81 ,  A61K38/57 ,  A61K45/06 ,  C07K14/4354 ,  C07K14/8146 ,  A61K38/00

摘要： A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C-S-C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.

公开(公告)号：US11946053B2

公开(公告)日：2024-04-02

申请号：US16590588

申请日：2019-10-02

申请人： St. Jude Children's Research Hospital, Inc.

发明人： Steven W. Paugh ,  William E. Evans ,  Erik Bonten

IPC分类号： A61K48/00 ,  A61K31/197 ,  A61K31/198 ,  A61K31/401 ,  A61K31/4025 ,  A61K31/551 ,  A61K31/573 ,  A61K31/713 ,  A61K38/06 ,  A61K38/07 ,  A61K38/57 ,  A61K45/06 ,  A61P5/44 ,  C12N15/113 ,  C12Q1/6886

CPC分类号： C12N15/1137 ,  A61K31/197 ,  A61K31/198 ,  A61K31/401 ,  A61K31/4025 ,  A61K31/551 ,  A61K31/573 ,  A61K31/713 ,  A61K38/06 ,  A61K38/07 ,  A61K38/57 ,  A61K45/06 ,  A61P5/44 ,  C12Q1/6886 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/158 ,  A61K31/573 ,  A61K2300/00 ,  A61K31/198 ,  A61K2300/00 ,  A61K31/401 ,  A61K2300/00 ,  A61K31/4025 ,  A61K2300/00 ,  A61K31/197 ,  A61K2300/00 ,  A61K31/551 ,  A61K2300/00 ,  C12N2310/14 ,  C12N2310/531

摘要： The invention provides methods for overcoming glucocorticoid resistance of cancers by inhibition of CASP1. Also disclosed are diagnostic methods for determining glucocorticoid resistance potential by measuring expression level or promoter methylation status of CASP1 gene and/or NLRP3 gene.

公开(公告)号：US20240058391A1

公开(公告)日：2024-02-22

申请号：US18141056

申请日：2023-04-28

申请人： Prime Merger Sub, LLC

发明人： Jeffrey S. WHITE ,  Robin R. Young

IPC分类号： A61K35/50 ,  A61K38/57 ,  A61L27/54 ,  A61L27/36

CPC分类号： A61K35/50 ,  A61K38/57 ,  A61L27/54 ,  A61L27/3604 ,  A61K9/0019

摘要： Methods for treating joint diseases, disorders, and conditions, such as osteoarthritis, with a composition containing a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) are provided. The composition can contain TIMPs as part of amniotic fluid, or the TIMPs can be isolated from another source or recombinantly produced. The methods are particularly useful for treating osteoarthritis associated with degradation of articular cartilage by proteases. Also provided are methods of lubricating a joint, such as an osteoarthritic joint.

公开(公告)号：US20240000908A1

公开(公告)日：2024-01-04

申请号：US18253485

申请日：2021-11-18

申请人： CSL Behring GmbH

发明人： John Roberts ,  Marc Uknis ,  Christine Voigt

IPC分类号： A61K38/57 ,  A61P37/06

CPC分类号： A61K38/57 ,  A61P37/06

摘要： The invention relates to methods of treating antibody-mediated rejection in a subject comprising administering C1-INH to the subject according to a schedule with the following steps: (a) intravenously administering one or more iv-doses of C1-INH, (b) subcutaneously administering at least 10 sc-doses of C1-INH over several weeks, wherein each week at least one sc-dose is administered. The invention further relates to a method of treating antibody-mediated rejection in a transplant recipient comprising subcutaneously administering C1-INH over at least 10 weeks, wherein each week at least one sc-dose is administered.